NOT-FD-23-005: Notice to Extend the Letter of Intent and Application Due Date for RFA-FD-23-006 - Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01)

Notice to Extend the Letter of Intent and Application Due Date for RFA-FD-23-006 - Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01)

Notice Number:

NOT-FD-23-005

Key Dates

Release Date:

January 17, 2023

Related Announcements

RFA-FD-23-006 - Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01) Clinical Trial Optional

Issued by

FOOD AND DRUG ADMINISTRATION (FDA)

Purpose

Notice to Extend the Letter of Intent and Application Due Date for RFA-FD-23-006 - "Applied Regulatory Science Research to Understand Factors that Affect the Safety and Efficacy of Underrepresented Populations in Oncology Therapeutic Development (U01)"

New Letter of Intent Due Date(s)

February 24, 2023

Technical Session

March 2023?

New Application Due Date(s)

April 3, 2023, by 11:59 PM Eastern Time.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.

Late applications will not be accepted for this FOA.

Inquiries

Please direct all inquiries to:

Shashi Malhotra
Food and Drug Administration
Office of Operations, Office of Finance Budget & Acquisitions
Office of Grants and Acquisition Services
Tel: 301-402-7592
Email: Shashi.Malhotra@fda.hhs.gov